Mutational spectrum
The following percentages are referred to patients with non-chromosomic, non-syndromic HPE.
Point mutations and microrearrangements in the four main genes in B27% of isolated HPE cases (SHH B12%, ZIC2 B9%, SIX3 B5%, TGIF B1%).
Alterations in minor genes o1%. These minor genes with low mutation frequency rates are tested only in selected cases: for example, GLI2 is tested when specific abnormalities occur in the development of the pituitary gland, in the context of variable brain and craniofacial anomalies consistent with the broad spectrum of HPE. 1 
Analytical methods
Search for point mutations: D-HPLC (denaturing high-performance liquid chromatography) or HRM (high-resolution DNA melting) with confirmation by sequencing, or direct bi-directional sequencing.
Search for microrearrangements: MLPA (multiplex ligation-dependent probe amplification) with SALSA Kit P187 Holoprosencephaly (MRC-Holland, Amsterdam, the Netherlands) or FISH (fluorescence in situ hybridization).
Analytical validation
Parallel analysis of positive and negative controls, depending on analytical method.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence):
1:10-16000 live births; 1:250 conceptuses.
1.9 If applicable, prevalence in the ethnic group of investigated person Ethnic variations in birth prevalence rates could occur in HPE, but the available data are not convincing. Higher rates were generally observed among less favored minorities, probably because of a lower prenatal detection rate of HPE, and consequently less terminations of pregnancy. 2 
Diagnostic setting
Comment: Prenatal diagnosis is based primarily on fetal imaging, but 'molecular' prenatal diagnosis can be performed if a mutation or a microrearrangement has been previously identified in a proband.
Interpretations of molecular diagnosis must be given with caution, given the lack of strict genotype-phenotype correlation, and should be offered in addition to fetal imaging, using ultrasound followed by fetal regional medical imaging. 
TEST CHARACTERISTICS

Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be performed case by case. By testing the four main genes, mutations are identified in B27% of isolated HPE cases.
Mutations in SHH are identified in B12% of propositi (10-30% de novo). The presence of structural brain anomalies in patients with SHH mutations is estimated to be B45%, whereas the penetrance of any manifestations (including microform HPE) is estimated to be B90%.
Mutations in ZIC2 are estimated to occur in up to 9% of propositi (72% de novo). Almost 90% of patients with mutations in ZIC2 have structural brain anomalies, and it is rare that a parent with a mutation will not show clear signs of cognitive impairment.
Mutations in SIX3 are estimated to occur in up to 5% of propositi (only 14% de novo). About 65% of patients with mutations in SIX3 have structural brain anomalies, most likely alobar rather than semilobar HPE.
Of the four genes commonly tested in clinical laboratories, mutations in TGIF are the least common, occurring in B1% of propositi. The role that alterations in TGIF have is not well understood.
Statistical analysis of combined results showed that propositi with structural brain anomalies who have either alobar or semilobar HPE are more likely to have a ZIC2 mutation, whereas SHH mutations seem to be responsible for most microform HPE. 3 In a research context, further analysis include subtelomeres exploration using MLPA, and array comparative genome hybridization.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be performed case by case.
Close to 100% for SHH, ZIC2 and SIX3 alterations, if the biological meaning of variation has been ascertained by robust functional analyses.
The role of TGIF is less clear.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
Non-chromosomal, non-syndromic HPE is classically considered an autosomal dominant condition with incomplete penetrance and highly variable expressivity. The spectrum of the effects of a single mutation within a single kindred is very wide. Recent data point to a complex pattern of inheritance combining multiple interacting genetic and environmental factors. 3 Therefore, because of this multihit hypothesis, not all carriers of a single deleterious mutation manifest clinically detectable symptoms. The identified mutation may be not sufficient to generate HPE, another event similar to an alteration in another gene (not yet identified) or an environmental factor being necessary.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a nonaffected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Close to 100% if the biological meaning of the identified family variation has been ascertained by robust functional analyses.
Index case in that family had not been tested: Not resolved. 4 In prenatal, ultrasound can detect central nervous system and facail abnormalities of severe HPE as early as the first trimester, but is less sensitive for detection of milder forms of HPE, such as lobar HPE. Fetal MRI provide better characterization of brain malformations, but only later in the third trimester of pregnancy. 5 3. Depending on clinical symptoms: cerebrospinal fluid shunt for treatment of hydrocephalus; antiepileptic medication; physical therapy, bracing and orthopedic surgery for motor impairment, anticholinergic drugs for dystonia; gastrostomy for oromotor dysfunction; tracheostomy for treatment of upper airway obstruction due to facial anomalies; H2 blockers or proton-pump inhibitors for gastrointestinal problems; modifying of the environment for hypothalamic dysfunction; hormones. 6 Prognosis (please describe)
CLINICAL UTILITY
Higher mortality correlates with several factors, including the severity of brain malformation, the severity of facial malformation, the presence of a multiple congenital anomaly syndrome, and the presence of chromosomal abnormalities.
Survival is associated with the severity of brain malformation (short for alobar, intermediate for semilobar and the best for lobar holoprosencephaly and mild forms). 6 Management (please describe)
The results of genetic tests will influence genetic counseling by permitting 'prenatal' diagnosis.
